Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033 | Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $2.99 billion in 2023 to $3.45 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $6.12 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp

Market Segmentation:
The main classes of drugs used in severe acute respiratory-syndrome treatment are antibiotics, antivirals, corticosteroids, monoclonal antibodies and others. Antibiotics refer to a class of medications used to treat bacterial infections. They work by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. They are administered through oral and intravenous routes for the treatment of severe acute respiratory syndrome COVID-19 (SARS-CoV) and severe acute respiratory syndrome COVID-19 2 (SARS-CoV 2). These are distributed through hospital pharmacies, retail pharmacies and others.

Major Driver - Surging Respiratory Disease Cases Fuel Growth In The Severe Acute Respiratory Syndrome Treatment Market
The growing incidence of respiratory diseases is expected to propel the growth of the severe acute respiratory syndrome treatment market going forward. Respiratory diseases refer to a group of medical conditions that affect the respiratory system responsible for breathing and the exchange of gases between the body and the external environment. Severe acute respiratory syndrome treatment is used in respiratory diseases to alleviate symptoms, prevent respiratory failure, reduce inflammation and maintain oxygen levels. For instance, in June 2023, according to reports shared by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021 in Australia. Therefore, the growing incidence of respiratory diseases is driving the growth of the severe acute respiratory syndrome treatment market.

Competitive Landscape:
Major players in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Top Trend - Leading Companies In The Severe Acute Respiratory Syndrome Treatment Market Pioneering Multiplexed Real-Time Pcr Techniques
Major companies operating in the severe acute respiratory syndrome treatment market are developing innovative techniques, such as multiplexed real-time PCR, to sustain their position in the market. Multiplexed real-time PCR is a molecular biology technology that permits the amplification and detection of numerous DNA or RNA targets in a single procedure. For instance, in July 2022, TransGen Biotech Co. Ltd., a Beijing-based researcher and manufacturer of molecular and cellular biology products, launched the Trans-SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus Assay. This innovative assay is a multiplexed real-time PCR (polymerase chain reaction) assay that can be used to detect and differentiate between severe acute respiratory syndrome COVID-19 2 (SARS CoV 2), Influenza A, Influenza B and respiratory syncytial virus (RSV) in a single specimen. Additionally, it is a valuable tool for diagnosing and treating SARS, influenza and RSV, which can help guide treatment and prevent the spread of these diseases.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Severe Acute Respiratory-Syndrome Treatment Market Characteristics
3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies
4. Severe Acute Respiratory-Syndrome Treatment Market - Macro Economic Scenario
5. Severe Acute Respiratory-Syndrome Treatment Market Size And Growth
…..
27. Severe Acute Respiratory-Syndrome Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.